Literature DB >> 12949746

IBD indirect costs: the sleeping giant?

Russel D Cohen.   

Abstract

Mesh：

Year:  2003        PMID： 12949746     DOI： 10.1016/s0016-5085(03)01127-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  2 in total

Review 1.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.